Safety, Tolerability, and Pharmacokinetics of a Subcutaneous and Intravenous Dose of BI 655130 in Healthy Subjects
- Conditions
- Healthy
- Interventions
- Drug: BI 655130
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT03100903
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
- Conditions
- NeoplasmsBreast Neoplasms
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 133
- Registration Number
- NCT03099174
- Locations
- 🇺🇸
University of California Los Angeles, Santa Monica, California, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT03100864
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, United Kingdom
🇩🇪Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany
🇧🇪UZ Leuven, Leuven, Belgium
Clinical Characteristics and Practice Patterns of Type 2 Diabetes Mellitus Patients Treated With OADs in Japan: Analysis of Medical and Health Care Database of the MDV
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: oral antidiabetic drugs
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 162116
- Registration Number
- NCT03092752
- Locations
- 🇯🇵
Medical Data Vision Co. Ltd, Shinagawa-ku, Japan
Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT03086356
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
DDI Strong CYP3A4 Inducer
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT03082183
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Real World Data on Management of Male LUTS
- Conditions
- Benign Prostatic Hyperplasia
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 201
- Registration Number
- NCT03075449
- Locations
- 🇺🇸
527.87.10001 Boehringer Ingelheim Investigational Site, Lexington, Kentucky, United States
Investigating Idiopathic Pulmonary Fibrosis in Greece
- Conditions
- Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 301
- Registration Number
- NCT03074149
- Locations
- 🇬🇷
Gen. Hosp. of Chest Diseases "Sotiria", Univ. Resp. Med., Athens, Greece
🇬🇷University Hospital of Heraklion, University Pulmonology Cl, Heraklion, Greece
🇬🇷General University Hospital of Larissa, Larissa, Greece
Comparison of the Bioavailability of Diclofenac in a Combination Product (Diclofenac 2% + Capsaicin 0.075% Topical Gel) With Two Diclofenac Only Products, Diclofenac Mono Gel 2% and Voltarol® 12 Hour Emulgel 2.32% Gel, in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT03074162
- Locations
- 🇿🇦
Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein, South Africa
Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 160
- Registration Number
- NCT03070171
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan